doi:10.1080/00365513.2020.1804610 Kanth VV, Golla JP, Sastry BK, et al
American Medical Association: What Doctors Wish Patients Knew About Anti-Obesity Medication Harvard Health Publishing: GLP-1 Diabetes and Weight Loss Drug Side Effects U.S
BIGUANIDES Metformin has remained first-line treatment for T2DM due to its efficacy, safety, duration of evidence, affordability, and limited side-effect profile
The mechanisms by which these supplements claim to work lack the robust scientific validation required for therapeutic claims
Standard-dose tirzepatide is usually selected when the patient wants stronger appetite and metabolic support through both GLP-1 and GIP pathways
November 13, 2024 As per the terms of the agreement, Novo Nordisk has gained the right to expand any resulting metabolic-disease products into other therapeutic areas